‘Paying Twice’: A Push for Affordable Prices for Taxpayer-Funded Drugs
On Aug. 30, the Food and Drug Administration approved a radical new cancer treatment that harnesses a patient’s immune system to attack tumor cells. The drug, known as Kymriah, grew out of research conducted and supported by the National Institutes of Health.
